Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions.
- 1 July 2005
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 3 (3) , 301-3
- https://doi.org/10.2174/1570161054368553
Abstract
Abstract: Poly(ADP-ribose) polymerase (PARP) activation plays a role in the pathogenesis of various cardiovascular and inflammatory diseases. Reactive oxygen and nitrogen species induce DNA single strand breaks, which serve as obligatory triggers for the activation of PARP. Pharmacological inhibitors of PARP attenuate ischemic and inflammatory cell and organ injury, and this property of the PARP inhibitors can be exploited for the experimental therapy of disease. As several classes of PARP inhibitors move towards clinical development, or have already entered clinical trials, we expect that inKeywords
This publication has 0 references indexed in Scilit: